pertuzumab + Trastuzumab + Capecitabine + Paclitaxel + Vinorelbine + Docetaxel + Exemestane + Letrozole + Anastrozole + Fulvestrant + Ribociclib + nab-Paclitaxel + eribulin + leuprorelin + goserelin
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Sep 1, 2015 → Jan 31, 2025
NCT ID
NCT02344472About pertuzumab + Trastuzumab + Capecitabine + Paclitaxel + Vinorelbine + Docetaxel + Exemestane + Letrozole + Anastrozole + Fulvestrant + Ribociclib + nab-Paclitaxel + eribulin + leuprorelin + goserelin
pertuzumab + Trastuzumab + Capecitabine + Paclitaxel + Vinorelbine + Docetaxel + Exemestane + Letrozole + Anastrozole + Fulvestrant + Ribociclib + nab-Paclitaxel + eribulin + leuprorelin + goserelin is a phase 3 stage product being developed by Eisai for Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02344472. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02344472 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Breast Cancer